Bingham Osborn & Scarborough LLC boosted its position in Amgen, Inc. (NASDAQ:AMGN) by 2.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,873 shares of the medical research company’s stock after purchasing an additional 60 shares during the quarter. Bingham Osborn & Scarborough LLC’s holdings in Amgen were worth $556,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Amgen by 3.4% in the 2nd quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock valued at $8,793,346,000 after purchasing an additional 1,585,911 shares during the period. Morgan Stanley raised its holdings in Amgen by 0.5% in the 2nd quarter. Morgan Stanley now owns 6,753,145 shares of the medical research company’s stock valued at $1,244,470,000 after acquiring an additional 34,674 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in Amgen by 1,334.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock valued at $910,860,000 after acquiring an additional 4,598,329 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Amgen by 9.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,780,461 shares of the medical research company’s stock valued at $512,383,000 after acquiring an additional 239,576 shares in the last quarter. Finally, Putnam Investments LLC raised its holdings in Amgen by 8.9% in the 2nd quarter. Putnam Investments LLC now owns 1,851,073 shares of the medical research company’s stock valued at $341,116,000 after acquiring an additional 151,910 shares in the last quarter. Institutional investors and hedge funds own 76.33% of the company’s stock.

Several brokerages have weighed in on AMGN. BidaskClub raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, November 1st. William Blair reaffirmed a “hold” rating on shares of Amgen in a report on Friday, August 30th. Citigroup reaffirmed a “buy” rating on shares of Amgen in a report on Monday, August 12th. Goldman Sachs Group set a $243.00 price objective on Amgen and gave the company a “buy” rating in a report on Monday, September 30th. Finally, Oppenheimer set a $240.00 price objective on Amgen and gave the company a “buy” rating in a report on Monday, September 9th. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Amgen currently has a consensus rating of “Buy” and an average price target of $219.56.

In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $193.58, for a total transaction of $387,160.00. Following the sale, the director now owns 16,436 shares in the company, valued at approximately $3,181,680.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total value of $91,566.25. Following the sale, the director now owns 5,413 shares in the company, valued at approximately $1,166,230.85. The disclosure for this sale can be found here. Insiders have sold a total of 17,851 shares of company stock valued at $3,685,674 in the last three months. 0.25% of the stock is owned by insiders.

Shares of Amgen stock traded up $3.12 during trading on Friday, reaching $221.11. 2,069,900 shares of the company’s stock were exchanged, compared to its average volume of 2,911,719. The company has a debt-to-equity ratio of 2.54, a quick ratio of 2.59 and a current ratio of 2.89. Amgen, Inc. has a 1-year low of $166.30 and a 1-year high of $221.25. The company has a market cap of $127.80 billion, a P/E ratio of 15.35, a PEG ratio of 2.21 and a beta of 1.09. The firm’s 50-day moving average price is $202.75 and its 200 day moving average price is $188.90.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, topping analysts’ consensus estimates of $3.53 by $0.13. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.63 billion. During the same quarter in the previous year, the firm earned $3.69 EPS. Amgen’s revenue was down 2.8% on a year-over-year basis. As a group, equities research analysts predict that Amgen, Inc. will post 14.44 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Stockholders of record on Friday, November 15th will be issued a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.62%. Amgen’s dividend payout ratio (DPR) is currently 40.28%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: How the Consumer Price Index (CPI) is calculated?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.